<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457532</url>
  </required_header>
  <id_info>
    <org_study_id>SCC244-104</org_study_id>
    <nct_id>NCT03457532</nct_id>
  </id_info>
  <brief_title>A Phase I Study of SCC244</brief_title>
  <official_title>A Multi-center, Open-label, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of SCC244 in Advanced Solid Tumors Patients With c-MET Alteration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ShangHai HaiHe Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ShangHai HaiHe Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability,
      pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with
      c-MET alteration
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT(Dose limit toxity)</measure>
    <time_frame>35 days</time_frame>
    <description>To evaluate the DLT in patients with advanced solid tumor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD(Max tolerance does)</measure>
    <time_frame>35 days</time_frame>
    <description>To evaluate the MTD in patients with advanced solid tumor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BED(Biological effective dose)</measure>
    <time_frame>35 days</time_frame>
    <description>To evaluate the BED in patients with advanced solid tumor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the ORR in patients with advanced solid tumor in Ib</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose escalation study of Glumetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the maximum tolerated dose (MTD) of Glumetinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glumetinib for tablet</intervention_name>
    <description>25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)</description>
    <arm_group_label>Dose escalation study of Glumetinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion:

          1. Evidence of a personally signed and dated informed consent document indicating that
             the subject (or a legal representative) has been informed of all pertinent aspects of
             the study.

          2. Male and/or female subjects of non-childbearing potential between the ages of 18 and
             70 years, inclusive.

          3. Life expectancy ≥ 12 weeks by the Investigator's judgment

          4. Locally advanced or metastatic solid tumor patients who have failed or relapsed on
             current standard of care for Phase 1a and advanced solid tumor patients who have
             failed or relapsed on current standard of care for Phase 1b.

          5. Patients with c-MET alteration：1) c-MET amplification; 2) c-MET over-expression or 3）
             c-MET axon 14 skipping.

          6. At least 1 measurable target lesion on the baseline scan as per RECIST 1.1

          7. Available qualified tissue sample (either fresh biopsy or archival tissue sample) is
             mandatory for phase Ib period, while fine needle aspiration and cytology samples are
             not sufficient for study eligibility screening.

          8. For phase Ia stage, ECOG performance score 0-1; For phase Ib stage, ECOG performance
             score 0-2

          9. Adequate organ function as documented

         10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests and other trial procedures.

         11. International normalized ratio (INR) ≤ 1.5, or activated partial thromboplastin time
             (aPTT) ≤ 1.5 ULN

        Main Exlcusion:

          1. Pregnant (serum human chorionic gonadotropin positive) or breastfeeding female
             patient.

          2. Prior received anti-tumor treatment, including anticancer drugs for the treatment
             within 28 days of first dose of study treatment or 5 half-lives of the agent,
             whichever is longer

          3. Prior received major surgery within 4 weeks of the first does.

          4. Palliative radiotherapy to bone metastasis within 4 weeks of the first does.

          5. Prior treated with another c-Met inhibitor

          6. Prior or concomitant other malignant tumor (except effectively controlled non-melanoma
             skin cancer, breast carcinoma in situ or cervix cancer in situ and superficial bladder
             cancer within past 5 years).

          7. Cardiac function impairment or clinically significant heart disease including
             congestive heart-failure ≥ Grade 2 according to grading of New York Heart Association,
             arrhythmia, conduction disorders requiring treatment, myocardium diseases, unstable
             angina or uncontrollable hypertension within 6 months prior to screening.

          8. QTcF-prolongation &gt; 470 msec; or has risk factors for Torsades De Pointe, hypokalemia
             (serum potassium &lt;3.0 mmol/L) or family history of long-QT-Syndrome

          9. History of stroke within 6 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JIN LI, M.D</last_name>
    <phone>021-38804518</phone>
    <phone_ext>22229</phone_ext>
    <email>lijin@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai East hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, M.D.</last_name>
      <phone>+86-021-38804518</phone>
      <phone_ext>22229</phone_ext>
      <email>lijin@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Jin Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety, Tolerability, Pharmacokinetics, Anti-tumor Activity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

